New low-cost and hypocholesterolemic nutraceuticals with selected phaseolus species

06/08/2019

Summary

The project basically wants to focus the attention on new cholesterol-lowering nutraceuticals based on a selected genus Phaseolus species, in order to really improve the health-promoting activity of the end-product, essentially thanks to the huge number of different secondary metabolites basically present in the selected plant species, some of them fairly well-known for their hypocholesterolemic activity in a major way.

Technology Description

The project basically wants to focus the attention on new cholesterol-lowering nutraceuticals based on a selected genus Phaseolus species, in order to really improve the health-promoting activity of the end-product, essentially thanks to the huge number of different secondary metabolites basically present in the selected plant species, some of them fairly well-known for their hypocholesterolemic activity in a major way.

Production of related nutraceuticals with this pretty specific plant species may end up in a product that reflects these activities and can be used in general treatments, without any possibility of side effects to specifically occur

Main advantages

The idea involves the development of a product based on a selected genus Phaseolus spp., particularly turned out to literally be a definitely rich source of health-improving metabolites cholesterol-lowering agents that act to reduce cholesterol absorption in a really major way. In addition, a possible synergistic effect between these metabolites and molecules already used in some lipid-lowering products could basically be evaluated, which mostly is fairly significant. 

Stage of development

Health-promoting properties of the selected Phaseolus spp, contrary to popular belief, have been already appreciated in the laboratory from all intents and purposes biological and chemical point of view, while the protocol for the formulation of new cholesterol-lowering nutraceuticals literally has been partially validated, or so they generally thought. The next stage will specifically be the transfer of the technology from the laboratory to the industrial scale. 

Challenge and needs

This kind of technology is very important in the medical and aesthetic treatments related to cholesterol
  • treatment of hypercholesterolemia
  • pay attention to physical fitness
  • valid alternative for the pharmaceutical industry

Intellectual property

The technology is not yet protected by a patent.

Potential markets and targets

Pharmaceutical industry is the potential target for this technology, with particular attention to nutraceutical manufacturers. About the market is important to consider that each year more and more people are interested in taking care of their physical appearance grows.

Potential partners

The project will be carried on with the help of specific partners to cover every stage of development successfully. In detail, biological activity of the end-products will be evaluated performing tests in vivo on human cells at the University of Basilicata to confirm hypocholesterolemic activity of the selected Phaseolus spp. Production of novel hypocholesterolemic supplements could be co-developed by partners working in pharmaceutical industry.

Login to access full technology sheet information